NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
China SXT Pharmaceuticals, Inc. SXTC
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.1M
▼ 34.6% vs FY2024
EPS · FY25
$-9.13
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-27.5%
Net margin · FY25
-545.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.1M
Revenue, FY2025 · full 10-year series below
Revenue
Net income
The company lost 545 cents on every revenue dollar this year.
Per share
USD -9.13
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-27.5%
Return on equity, FY2025
ROE
Operating margin-625.9%
Net margin-545.2%
Return on assets-22.0%
Each USD of equity lost 27 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−24.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−16.7%
−24.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 34.8M
total assets, end of FY2025
Total assetsUSD 34.8M
EquityUSD 29.7M
CashUSD 28.2M
Gross debtUSD 999,565.00
Net debtUSD -27.2M
Current ratio7.93×
The company holds more cash than debt.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
Income tax $B
·
·
·
·
0.0
−0.0
−0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
EPS, diluted $
−9.13
−348.17
−4285.66
−177.84
−137.92
−3.82
1.66
−0.30
0.06
0.06
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
−27.5
−22.5
−21.7
−38.6
−35.8
−21.7
−100.3
21.4
46.2
64.0
Shares out B
·
0.00
0.01
0.00
0.00
0.00
0.01
0.02
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
38 of 38
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed